Thymopentin therapy reduces the clinical severity of atopic dermatitis
DYM Leung, RL Hirsch, L Schneider, C Moody… - Journal of Allergy and …, 1990 - Elsevier
One hundred patients with moderate to severe atopic dermatitis were entered into a two-
center, double-blind trial. Patients were randomized to receive either thymopentin (Timunox,
n= 48) or placebo (n= 52), administered as daily subcutaneous injections for 6 weeks.
Clinical extent of disease and severity parameters were measured at baseline and at regular
time intervals during the study. Both the placebo-and thymopentin-treated groups
demonstrated a progressive and statistically significant (p< 0.001) decline in the overall …
center, double-blind trial. Patients were randomized to receive either thymopentin (Timunox,
n= 48) or placebo (n= 52), administered as daily subcutaneous injections for 6 weeks.
Clinical extent of disease and severity parameters were measured at baseline and at regular
time intervals during the study. Both the placebo-and thymopentin-treated groups
demonstrated a progressive and statistically significant (p< 0.001) decline in the overall …
